Table 5 Results of scenario analyses over 2002–2012 (2009 excluded) for total recommended population (n = 7,423,675)
From: Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
Total over the period (% variation compared to base case) | |||
|---|---|---|---|
Base case | Scenario 1 | Scenario 2 | |
Outcomes avoided | |||
Influenza cases | 68,271 | 58,468 (−14 %) | 68,271 (0 %) |
GP consultations | 47,537 | 40,711 (−14 %) | 47,537 (0 %) |
Working days lost | 33,091 | 28,339 (−14 %) | 33,091 (0 %) |
Hospitalisations | 3,522 | 3,016 (−14 %) | 4,095 (16 %) |
Deaths | 683 | 585 (−14 %) | 693 (1 %) |
Influenza-related cost offsets (in A$) | |||
GP consultations | $1,761,250 | $1,508,357 (−14 %) | $1,761,250 (0 %) |
Hospitalisations | $34,741,889 | $29,750,615 (−14 %) | $38,300,256 (10 %) |
Income loss | $10,010,133 | $8,572,811 (−14 %) | $10,010,133 (0 %) |
Total societal costs | $46,513,271 | $39,831,784 (−14 %) | $50,071,639 (8 %) |